International Biopharmaceutical Company Selects OmniComm’s TrialMaster® EDC for Multi-Study Cancer Research
FORT LAUDERDALE, Fla., Nov. 27, 2018 (GLOBE NEWSWIRE) -- An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology. Under the agreement, the biopharma company will initially use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment.
TrialMaster EDC was selected as one of the pharmaceutical company’s preferred EDC systems based on the system’s inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important. OmniComm’s robust, state-of-the-art, compliant hosting environment was another critical factor in the selection process.
“Once again, TrialMaster EDC has been selected after a rigorous evaluation process and been found to have the best-in-class technology,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “The clever way TrialMaster has been designed offers our users an easily scalable solution across the full gamut of phases and study design in oncology.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information, and follow OmniComm on Twitter: @OmniCommSystems, on LinkedIn: @OmniComm Systems and Facebook: @OmniComm Systems, Inc.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact InfoKuno van der PostOmniComm Systems, Inc. +1.954.473.1254KvanderPost@omnicomm.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
